These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12923404)

  • 41. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
    Iino Y; Hayashi M; Kawamura T; Shiigai T; Tomino Y; Yamada K; Kitajima T; Ideura T; Koyama A; Sugisaki T; Suzuki H; Umemura S; Kawaguchi Y; Uchida S; Kuwahara M; Yamazaki T;
    Clin Exp Nephrol; 2003 Sep; 7(3):221-30. PubMed ID: 14586719
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Moxonidine and cognitive function: interactions with moclobemide and lorazepam.
    Wesnes K; Simpson PM; Jansson B; Grahnén A; Weimann HJ; Küppers H
    Eur J Clin Pharmacol; 1997; 52(5):351-8. PubMed ID: 9272403
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hypertension and chronic renal failure: the use of ACE inhibitors.
    Porush JG
    Am J Kidney Dis; 1998 Jan; 31(1):177-84. PubMed ID: 9428471
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A multicenter, randomized, double-blind, placebo-controlled, two-year trial to study the effect of nitrendipine on chronic renal transplant function.
    Barenbrock M; Colmorgen U; Firschka E; Gellert J; Lippert J; Schröder K; Spieker C; Voigt-Ladner G; Wagner K; Neumayer HH
    Clin Nephrol; 1995 Jun; 43(6):388-91. PubMed ID: 7554523
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure.
    Kindler J; Schunkert H; Gassmann M; Lahn W; Irmisch R; Debusmann ER; Ocón-Pujadas J; Ritz E; Sieberth HG
    J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S55-8. PubMed ID: 2474105
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
    Schrader J; Lüders S; Kulschewski A; Hammersen F; Plate K; Berger J; Zidek W; Dominiak P; Diener HC;
    Stroke; 2005 Jun; 36(6):1218-26. PubMed ID: 15879332
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients.
    Chan JC; Ko GT; Leung DH; Cheung RC; Cheung MY; So WY; Swaminathan R; Nicholls MG; Critchley JA; Cockram CS
    Kidney Int; 2000 Feb; 57(2):590-600. PubMed ID: 10652036
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients.
    Suwelack B; Kobelt V; Erfmann M; Hausberg M; Gerhardt U; Rahn KH; Hohage H
    Transpl Int; 2003 May; 16(5):313-20. PubMed ID: 12759722
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nitrendipine and enalapril in the treatment of diabetic hypertensive patients with microalbuminuria.
    Piñol C; Cobos A; Cases A; Esmatges E; Soler J; Closas J; Pascual R; Planas J
    Kidney Int Suppl; 1996 Jun; 55():S85-7. PubMed ID: 8743519
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients.
    Abellán J; Leal M; Hernández-Menárguez F; García-Galbis JA; Martínez-Pastor A; de Vinuesa SG; Luño J
    Kidney Int Suppl; 2005 Jan; (93):S20-4. PubMed ID: 15613062
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
    Chazova I; Almazov VA; Shlyakhto E
    Diabetes Obes Metab; 2006 Jul; 8(4):456-65. PubMed ID: 16776753
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group.
    Lewis JB; Berl T; Bain RP; Rohde RD; Lewis EJ
    Am J Kidney Dis; 1999 Nov; 34(5):809-17. PubMed ID: 10561135
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group.
    Philipp T; Anlauf M; Distler A; Holzgreve H; Michaelis J; Wellek S
    BMJ; 1997 Jul; 315(7101):154-9. PubMed ID: 9251545
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency.
    Tong PC; Ko GT; Chan WB; Ma RC; So WY; Lo MK; Lee KF; Ozaki R; Chow CC; Cockram CS; Chan JC
    Diabetes Obes Metab; 2006 May; 8(3):342-7. PubMed ID: 16634995
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of sympatholytic therapy on postmenopausal symptoms in hypertensive postmenopausal women.
    Kujala SM; Pöyhönen-Alho M; Kaaja RJ
    Climacteric; 2014 Aug; 17(4):356-62. PubMed ID: 24099152
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Can angiotensin-converting enzyme inhibitor be used in chronic kidney disease patients with serum creatinine level greater than 266 micromol/L?].
    Zhang GH; Hou FF; Zhang X; Liu QF
    Zhonghua Nei Ke Za Zhi; 2005 Aug; 44(8):592-6. PubMed ID: 16194413
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The influence of renal function on clinical pharmacokinetics of moxonidine.
    Kirch W; Hutt HJ; Plänitz V
    Clin Pharmacokinet; 1988 Oct; 15(4):245-53. PubMed ID: 3191647
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Add-on angiotensin receptor blockade with maximized ACE inhibition.
    Agarwal R
    Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Twenty-four-hour blood pressure profiles in patients with mild-to-moderate hypertension: moxonidine versus captopril.
    Kraft K; Vetter H
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S29-33. PubMed ID: 7533224
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
    Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
    Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.